Avelumab in First Line Maintenance in Advanced Urothelial Carcinoma (aUC) in Elderly Patients: Efficacy, Tolerability, and Quality of Life in Real Life Setting

(1) Background Immune checkpoint inhibitors (ICIs) have recently become an important therapeutic option for patients with advanced urothelial carcinoma (aUC). Avelumab is an anti-PD-L1 (programmed cell death ligand 1) antibody that restores antitumor T-cell immune function by blocking the binding of...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Rossella De Luca, Pasquale Vitale, Alessio Pepe, Roberta Spedaliere, Alchiede Simonato, Raffaele Addeo, Giuseppe Cicero
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2024-11-01
Schriftenreihe:	Scientia Pharmaceutica
Schlagworte:	Avelumab immunotherapy advanced urothelial carcinoma progression free survival quality of life
Online-Zugang:	https://www.mdpi.com/2218-0532/92/4/62
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!